Recently approved Drug - U.S FDA

The U.S. Food and Drug Administration (FDA) has approved ATryn (Antithrombin [Recombinant]) for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.

Generic Name: Antithrombin [Recombinant]
Date of Approval: February 6, 2009
Company: GTC Biotherapeutics

Link: http://www.drugs.com/atryn.html